When: Price breaks above $116 with volume >7M and RSI >65

Then: Deploy final 40% tranche

When: Price closes above $118 with volume >10M shares

Then: Trim 15% position

HOLD

• MACD bearish cross at negative 0.66 with expanding negative histogram signals momentum deterioration, not noise; first close below 10 EMA since early August after three failures at 112-117 resistance zone
• Net debt rose from roughly 4.4 billion at year-end 2025 to an estimated 20 to 22 billion post-acquisition; 1.8x net debt to EBITDA ratio is the threshold where credit agencies pay attention
• Dividend payout ratio running around 76 percent of TTM EPS with operating margins compressed from 19 percent in 2022 to 14.7 percent TTM creates streak risk for Dividend Aristocrat
• Libre Duo 10-Day FDA approval and LAA device CE mark are already priced (ABT closed down 2.2 percent day after announcements); BSX cyberattack is one-quarter channel opportunity only
• Medicare CGM coverage decision is binary with asymmetric outcomes: 25 percent upside if approved vs 8 to 10 percent downside on disappointment or delay
• Adding at current 110.36 into deteriorating momentum places stop 7.4 percent away at 50 SMA (102-105); stressed exit scenario could see gaps to 95 or lower making true risk 12-15 percent
• Probability-weighted return at current levels is modest given bull targets at 132 with only 20 percent probability weighting; adds exposure without improving odds
• Collect 2.24 percent dividend yield while waiting for Q3 pre-announcement window in early October and integration clarity on the 20 billion deal

→ vs aggressive: MACD bearish cross dismissed as 'noise' is actually a pattern: negative 0.66 histogram with expanding negative bars signals losing buyer conviction, not statistical curiosity

→ vs aggressive: Free cash flow of 7.4 billion cited without addressing net debt transformation: post-deal leverage at 20-22 billion creates credit rating pressure at 1.8x threshold; Dividend Aristocrat downgrade triggers income investor mechanical rotation out

→ vs aggressive: Catalyst stack mischaracterized: FDA and CE mark approvals are regulatory milestones not revenue; ABT down 2.2 percent in green market day after announcements proves news was priced not missed

→ vs aggressive: Medicare coverage framed as 25 percent upside without acknowledging 8-10 percent downside on negative decision; binary catalyst with high positioning built around it creates asymmetric risk

→ vs aggressive: 'Add aggressively' at current 110.36 is equivalent to adding at 108-110 target zone; not disciplined scaling but buying a falling knife with first close below 10 EMA since early August

→ vs aggressive: Stop placement at 50 SMA (102-105) is 7.4 percent away but stressed exit scenarios show actual risk of 12-15 percent with gap-down potential to 95 or lower on catalyst miss

→ vs aggressive: Bull case at 137 equals prior 52-week high after 35 percent rally from lows; revisiting 52-week high is momentum thesis not fundamental thesis with modest probability-weighted return

HOLD with conditional tactical additions on technical stabilization; scaled approach with explicit entry levels and hard cap on maximum exposure

• Conditional HOLD rather than pure HOLD or aggressive BUY - acknowledge upside capture opportunity while managing risk
• Pre-authorize 25 to 30 percent of intended add on confirmed defense of 109.50 intraday low with RSI holding above 50 and MACD histogram contraction
• Tiered addition system replaces binary add zone: 30 percent at 109-110 on stabilization, 30 percent at 105-107 on 200 SMA test, 40 percent only on confirmed breakout above 116 with expanding volume and RSI pushing through 60
• Dismiss 137 price target as anchoring on different macro environment; probability-weighted expected return is modest even at 20 percent probability of 132
• Dismiss 102-105 add zone as not risk-free - any print there implies something broke (China pre-announce, Medicare delay, credit downgrade, or market weakness)
• Forward P/E of 18 times assumes market already pricing in normalization; 1.8x net debt to EBITDA at 7.4B free cash flow is manageable
• Integration execution and 76 percent payout ratio is the real risk - if margins don't expand by mid-2027, dividend growth slows materially
• 50 year dividend streak survived two recessions but 50 year streaks don't protect from 15 percent drawdown in risk-off tape
• Position sizing should target soft landing scenario, not bull case or bear case
• ABT's dual identity as defensive yield name with growth catalysts is an advantage in hawkish Fed regime (1 percent September cut probability)
• 8 percent recession probability is low but not zero; hold sizing for soft landing
• Never let position exceed moderate weight in portfolio - not enough yield to take concentrated risk

→ vs aggressive: Thesis fixation on 137 target ignores that it's set during different macro environment with less leverage and earlier CGM ramp stage; even with 20 percent odds of 132, probability-weighted expected return is modest

→ vs aggressive: Treating FDA and CE mark approvals as unpriced lottery tickets ignores that ABT closed down 2.2 percent in a green market right after announcements - that's what partially priced catalysts look like, not unpriced ones

→ vs aggressive: Dismissal of MACD bearish cross as 'just a reset' ignores this follows a 35 percent rally in three weeks; parabolic resets often become something more

→ vs aggressive: Adding at 110 into deteriorating momentum is not disciplined aggression - the aggressive can be right about direction but wrong about timing and sizing

→ vs conservative: Calling Libre Duo approval and LAA CE mark 'regulatory milestones, not revenue' is technically true but strategically meaningless; first-in-class FDA designations build durable competitive moats with multi-quarter channel windows

→ vs conservative: BSX disruption creates real opportunity for ABT electrophysiology team to capture sticky hospital vendor relationships - underselling the competitive angle

→ vs conservative: 51 year dividend streak surviving two recessions won't break due to margin compression from integration costs that are non-recurring and already explained by the market

→ vs conservative: Waiting for 102-105 add zone constructs narrative around dividend disappointment that is possible but not base case; creates opportunity cost of missing catalyst pricing in

→ vs conservative: 50 SMA re-test is a zone, not a guarantee; every day waiting is a day 18 percent Medicare probability and BSX share migration may be pricing in